Ferenci, P; Brunner, H; Laferl, H; Bergholz, U; Rosenbeiger, M; Stauber, R; Maieron, A; Fischer, G; Bischof, M; Steindl-Munda, P.
Further reduction of ribavirin dose in HCV genotype 2/3 patients receiving peginterferon alpha-2a (40KD) (PEGASYS (R)) plus ribavirin (COPEGUS (R)): Interim results of a randomised controlled trial
J HEPATOL. 44: S37-S37.-41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver; APR 26-30, 2006; Vienna, AUSTRIA.
Doi: 10.1016/S0168-8278(06)80083-8
[Oral Communication]
Web of Science
FullText
FullText_MUG